The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment

ConclusionsIn our study, p53 overexpression was associated with anti-EGFR treatment resistance in patients withRAS/BRAF WT mCRC, as confirmed in a validation cohort. Larger studies are needed to validate the role of p53 and investigate EGFR cross-talk in these patients.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research